CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,244,783
- in 2 filings, $3.2M under 10b5-1 plans
Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-06 | Aguilar-Cordova Estuardo Director | Option exercise · Stock Option (Right to Buy) | −46,261 | 30,456 | ||
| 2022-04-14 | Tyagarajan Seshu See Remarks | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2022-04-11 | Stewart Susan B. Chief Regulatory Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-02-28 | Canepa John J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2022-02-28 | Tak Paul Peter Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +330,000 | 330,000 | ||
| 2022-02-28 | Barone Francesca Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2022-02-03 | Barone Francesca Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2021-07-29 | Manning Paul B Director | Conversion | +679,158 | 679,158 | ||
| 2021-07-29 | Manning Paul B Director | Conversion | +553,752 | 553,752 | ||
| 2021-07-29 | Manning Paul B Director | Purchase | +1,625,000 | $8.00 | $13.0M | 1,681,000 |
| 2021-07-29 | Manning Paul B Director | Conversion · Series B Preferred Stock | −1,669,303 | 0 | ||
| 2021-07-29 | Manning Paul B Director | Conversion · Series B Preferred Stock | −1,361,069 | 0 | ||
| 2021-07-29 | Martell Christopher Director | Conversion | +283,514 | 283,514 | ||
| 2021-07-29 | Martell Christopher Director | Purchase | +125,000 | $8.00 | $1.0M | 125,000 |
| 2021-07-29 | Martell Christopher Director | Conversion · Series B Preferred Stock | −696,851 | 0 | ||
| 2021-07-29 | Aguilar-Cordova Estuardo Chief Scientific Officer | Conversion | +162,137 | 1,015,923 | ||
| 2021-07-29 | Aguilar-Cordova Estuardo Chief Scientific Officer | Conversion · Series B Preferred Stock | −398,519 | 0 | ||
| 2021-07-29 | Nguyen Diem Director | Purchase | +10,000 | $8.00 | $80K | 10,000 |
| 2021-07-29 | Tak Paul Peter Chief Executive Officer | Purchase | +25,000 | $8.00 | $200K | 25,000 |
| 2021-07-29 | Manning Paul B Director | Conversion | +679,158 | 679,158 |
Page 12 of 13 · 249 trades